Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 262

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

Open access
Fiedler, Walter, Mesters, Rolf, Tinnefeld, Heike, Loges, Sonja, Staib, Peter, Dührsen, Ulrich, Flasshove, Michael, Ottmann, Oliver G., Jung, Wolfram, Cavalli, Franco, Kuse, Rolf, Thomalla, Joerg, Serve, Hubert, O'Farrell, Anne M., Jacobs, Mark, Brega, Nicoletta M., Scigalla, Paul, Hossfeld, Dieter K., Berdel, Wolfgang E.·2003·Blood

Abstract

Neoangiogenesis has been shown to play an important role in the pathogenesis of acute myeloid leukemia (AML). Autocrine and paracrine secretion of angiogenic and hematopoietic growth factors such as vascular endothelial growth factor (VEGF) and stem cell factor (SCF) in the bone marrow microenvironment may promote proliferation and survival of leukemic blasts. This concept represented the rationale for the initiation of a multicenter phase 2 trial of SU5416, a small molecule inhibitor of phosphorylation of VEGF receptors 1 and 2, c-kit, the SCF receptor, and fms-like tyrosine kinase-3 (FLT3) in patients with advanced AML. Entered into the study were 43 patients with refractory AML or elderly patients not judged medically fit for intensive induction chemotherapy; 42 patients received at least one dose of study drug. Treatment was generally well tolerated, with nausea, headache, and bone pain the most frequent treatment-related side effects. One patient had a morphologic remission (French-American-British [FAB] criteria of complete response without normalization of blood neutrophil and platelet counts) lasting for 2 months. There were 7 patients who achieved a partial response (reduction of blasts by at least 50% in bone marrow and peripheral blood) lasting 1 to 5 months. Patients with AML blasts expressing high levels of VEGF mRNA by quantitative polymerase chain reaction (PCR) had a significantly higher response rate and reduction of bone marrow microvessel density than patients with low VEGF expression consistent with the antiangiogenic effects of SU5416.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2002-10-2998

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 262

Metadata

Authors
Fiedler, W., Mesters, R., Tinnefeld, H., Loges, S., Staib, P., Dührsen, U., Flasshove, M., Ottmann, O. G., Jung, W., Cavalli, F., Kuse, R., Thomalla, J., Serve, H., O'Farrell, A. M., Jacobs, M., Brega, N. M., Scigalla, P., Hossfeld, D. K., & Berdel, W. E.
Venue
Blood
Published
2003-10-15
Volume
102
Issue
8
Pages
2763-2767
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2118781121
Cited by
262
References
16
FWCI
15.29
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood-2002-10-2998
The paper
Fiedler, W., Mesters, R., Tinnefeld, H., Loges, S., Staib, P., Dührsen, U., Flasshove, M., Ottmann, O. G., Jung, W., Cavalli, F., Kuse, R., Thomalla, J., Serve, H., O'Farrell, A. M., Jacobs, M., Brega, N. M., Scigalla, P., Hossfeld, D. K., & Berdel, W. E. (2003). A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. https://doi.org/10.1182/blood-2002-10-2998

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.